Kidney Week

Abstract: FR-PO1117

Gout Prevalence and Management Strategies among Patients with Moderate to Advanced CKD

Session Information

• CKD: Epidemiology, Risk Factors, and Prevention - 2
  October 25, 2024 | Location: Exhibit Hall, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: CKD (Non-Dialysis)

• 2301 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention

Authors

• Laddu, Deepika, Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States

Deepika Laddu, PhD

• Sylvertooth, Dhajanae, Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States

Dhajanae Sylvertooth

• Guedes, Murilo Henrique, Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States

Murilo Henrique Guedes, MD, PhD

• Bieber, Brian, Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States

Brian Bieber, MPH

• Pecoits-Filho, Roberto, Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States

Roberto Pecoits-Filho, MD, PhD, FASN

• Marder, Bradley Allan, Amgen Inc, Thousand Oaks, California, United States

Bradley Allan Marder, MD

• LaMoreaux, Brian, Amgen Inc, Thousand Oaks, California, United States

Brian LaMoreaux, MD, MS

• Karaboyas, Angelo, Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States

Angelo Karaboyas, MS, PhD

Background

Gout, a hallmark clinical manifestation of hyperuricemia-induced inflammation in joints and soft tissue, frequently coexists with chronic kidney disease (CKD), potentially exacerbating as kidney function declines. Despite its growing global burden, there is limited data on gout monitoring and treatment practices among CKD patients. This multi-country study describes the prevalence, patient characteristics, and medical management of gout in a cohort of non-dialysis patients with moderate to advanced CKD.

Methods

Cross-sectional data from 3,524 non-dialysis stage 3b-5 CKD patients enrolled in the Chronic Kidney Disease Outcomes and Practice Patterns Study (CKDopps) in Brazil (n=942) and the United States (US; n=2,582) at study enrollment (2013-2022) were analyzed. History of gout (yes/no) was extracted from medical records by study coordinators. Patient characteristics, gout treatment, and uric acid measurement practices were summarized by gout diagnosis and country.

Results

Prevalence of gout was 19% overall – 21% in the US vs. 14% in Brazil – and was higher in stage 4-5 vs. stage 3b CKD in both countries (Figure). Gout patients (versus no gout) were more likely to be male (66% vs. 49%) and have a higher prevalence of cardiovascular comorbidities, despite similar BMI levels across groups. Among gout patients, allopurinol was the most utilized gout treatment in both Brazil (75%) and the US (62%). Colchicine (13%) and Febuxostat (8%) were also used in the US, but rarely in Brazil (<5%). Mean uric acid among gout patients was 7.0 mg/dL in Brazil vs. 6.7 mg/dL in the US; however, only 30% of US gout patients had a uric acid measurement, vs. 70% in Brazil.

Conclusion

Gout affects a substantial proportion of the non-dialysis CKD population, with differing management and monitoring strategies between the US and Brazil. Further examination of the effectiveness of gout diagnosis and treatment practices between countries may provide an important opportunity to improve patient outcomes.

Funding

• Commercial Support – Horizon Therapeutics plc (now Amgen, Inc.)